Japan Long-term Safety for Tiotropium Plus Olodaterol

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD).
Epistemonikos ID: b111bdaaf98d075b70a2f8abf992defcc2485c8d
First added on: Jun 24, 2019